



**HAL**  
open science

## Structural basis for human Cav3.2 inhibition by selective antagonists

Jian Huang, Xiao Fan, Xueqin Jin, Chen Lyu, Qinqing Guo, Tao Liu,  
Jiaofeng Chen, Amaël Davakan, Philippe Lory, Nieng Yan

► **To cite this version:**

Jian Huang, Xiao Fan, Xueqin Jin, Chen Lyu, Qinqing Guo, et al.. Structural basis for human Cav3.2 inhibition by selective antagonists. *Cell Research*, In press, 34 (6), pp.440-450. 10.1038/s41422-024-00959-8 . hal-04549967

**HAL Id: hal-04549967**

**<https://hal.science/hal-04549967>**

Submitted on 17 Apr 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## ARTICLE OPEN



# Structural basis for human Ca<sub>v</sub>3.2 inhibition by selective antagonists

Jian Huang<sup>1,6</sup>, Xiao Fan<sup>1,5,6</sup>, Xueqin Jin<sup>2,6</sup>, Chen Lyu<sup>2</sup>, Qinmeng Guo<sup>2</sup>, Tao Liu<sup>2</sup>, Jiaofeng Chen<sup>2</sup>, Amaël Davakan<sup>3</sup>, Philippe Lory<sup>3</sup> and Nieng Yan<sup>2,4</sup>

© The Author(s) 2024

The Ca<sub>v</sub>3.2 subtype of T-type calcium channels has been targeted for developing analgesics and anti-epileptics for its role in pain and epilepsy. Here we present the cryo-EM structures of Ca<sub>v</sub>3.2 alone and in complex with four T-type calcium channel selective antagonists with overall resolutions ranging from 2.8 Å to 3.2 Å. The four compounds display two binding poses. ACT-709478 and TTA-A2 both place their cyclopropylphenyl-containing ends in the central cavity to directly obstruct ion flow, meanwhile extending their polar tails into the IV-I fenestration. TTA-P2 and ML218 project their 3,5-dichlorobenzamide groups into the II-III fenestration and place their hydrophobic tails in the cavity to impede ion permeation. The fenestration-penetrating mode immediately affords an explanation for the state-dependent activities of these antagonists. Structure-guided mutational analysis identifies several key residues that determine the T-type preference of these drugs. The structures also suggest the role of an endogenous lipid in stabilizing drug binding in the central cavity.

*Cell Research* (2024) 0:1–11; <https://doi.org/10.1038/s41422-024-00959-8>

## INTRODUCTION

Voltage-gated calcium (Ca<sub>v</sub>) channels respond to membrane depolarization, allowing Ca<sup>2+</sup> influx and translating electrical signals into intracellular Ca<sup>2+</sup>-mediated events.<sup>1–4</sup> They play instrumental roles in Ca<sup>2+</sup>-dependent physiological processes such as neurotransmitter/hormone release, gene expression, and muscle contraction.<sup>3,5–9</sup> Precise control of calcium channel activity involves various cellular factors such as receptors, calmodulin, phospholipids, and G proteins.<sup>10–18</sup> Additionally, these channels can be modulated by a range of ions, toxins, and numerous clinical and investigational drugs.<sup>19–24</sup>

Among the 10 mammalian Ca<sub>v</sub> subtypes (Ca<sub>v</sub>1.1–Ca<sub>v</sub>1.4, Ca<sub>v</sub>2.1–Ca<sub>v</sub>2.3, and Ca<sub>v</sub>3.1–Ca<sub>v</sub>3.3), the Ca<sub>v</sub>3 subfamily, also known as the T-type calcium channels, is characterized by tiny and transient currents, in contrast to the large and long-lasting L-type Ca<sub>v</sub>1 channels.<sup>25–28</sup> Unlike Ca<sub>v</sub>1 and Ca<sub>v</sub>2 members, which require multiple auxiliary subunits for channel activities, the T-type channels function independently.<sup>29–31</sup> In addition, while Ca<sub>v</sub>1 and Ca<sub>v</sub>2 channels are activated at high voltage, thus also known as high voltage-activated (HVA) channels, Ca<sub>v</sub>3 channels are low voltage-activated (LVA).<sup>28,32,33</sup> Their functional distinctions are supported by a large degree of sequence variations between the LVA and HVA channels, offering an opportunity to develop subtype-specific modulators for potential drug discovery.

Ca<sub>v</sub>3.2, encoded by *CACNA1H* and widely expressed in the central nervous system, regulates neuronal excitability and participates in nociception.<sup>34,35</sup> Alterations in its activity are

associated with many neurological and neuropsychiatric disorders, including idiopathic generalized epilepsy and pain.<sup>36–39</sup> Studies indicate increased expression and/or activity of Ca<sub>v</sub>3.2 in spinal dorsal horn and in dorsal root ganglion neurons in various inflammatory and neuropathic pain models.<sup>36</sup> Silencing or pharmacological inhibition of Ca<sub>v</sub>3.2 channels induces analgesia in rodents.<sup>40</sup> Consequently, Ca<sub>v</sub>3.2 is emerging as a promising drug target for the development of next-generation analgesics. Compounds targeting Ca<sub>v</sub>3.2, such as ethosuximide, mibefradil, valproate, zonisamide, pimozide, and certain dihydropyridines (DHPs), demonstrate efficacy in rodent models of acute, inflammatory, and chronic pain.<sup>40–42</sup>

There are ongoing efforts to scrutinize various small molecules with novel chemical skeletons as potential analgesic candidates, such as Z944, TTA-A2, TTA-P2, ML218, and ACT-709478.<sup>43–46</sup> Compared to the approved drugs that usually have limited specificity for T-type channels, these investigational T-type-specific blockers demonstrate stronger affinities for T-type Ca<sub>v</sub> channels. Although these compounds have yet to discriminate between T-type subtypes, the distinctive pharmacokinetic properties of Ca<sub>v</sub>3.2, compared to Ca<sub>v</sub>3.1 and Ca<sub>v</sub>3.3, offer an opportunity to develop bona fide Ca<sub>v</sub>3.2-selective molecules.

Gaining high-resolution insights into the structures of channels complexed with FDA-approved drugs or lead compounds is crucial for guiding de novo drug design or optimization. The structure of Ca<sub>v</sub>3.1 bound to a lead compound Z944 reveals the basic architecture of the T-type channels and the molecular basis

<sup>1</sup>Department of Molecular Biology, Princeton University, Princeton, NJ, USA. <sup>2</sup>Beijing Frontier Research Center for Biological Structures, State Key Laboratory of Membrane Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China. <sup>3</sup>IGF, Université de Montpellier, CNRS, INSERM, LabEx 'Ion Channel Science and Therapeutics', Montpellier, France. <sup>4</sup>Institute of Bio-Architecture and Bio-Interactions, Shenzhen Medical Academy of Research and Translation, Shenzhen, Guangdong, China. <sup>5</sup>Present address: Laboratory of Neurophysiology and Behavior, The Rockefeller University, New York, NY, USA. <sup>6</sup>These authors contributed equally: Jian Huang, Xiao Fan, Xueqin Jin. ✉email: fanxiao0606@gmail.com; nyan@tsinghua.edu.cn

Received: 21 December 2023 Accepted: 2 April 2024

Published online: 11 April 2024

for the state-dependent inhibition of Ca<sub>v</sub>3 subfamily by Z944.<sup>44</sup> A recent report on the structures of Ca<sub>v</sub>3.3 in complex with mibefradil, pimoziide, and otilonium bromide broadens the spectrum of drug recognitions targeting T-type calcium channels.<sup>47</sup> In this study, we sought to determine the structures of human Ca<sub>v</sub>3.2 alone and in complex with representative antagonists, with a particular focus on those exhibiting enhanced selectivity for T-type calcium channels.

## RESULTS

### Structural determination of human Ca<sub>v</sub>3.2

The bottleneck in the structural analysis of human Ca<sub>v</sub>3.2 arises from the low yield of recombinant protein expression. To enhance protein production, various constructs were explored. The I-II loop plays an inhibitory role in Ca<sub>v</sub>3.2 expression and function.<sup>48,49</sup> We thereby introduced several internal truncations of different fragments to this region. Eventually, a variant with the deletion of residues 493–772 resulted in an elevated expression level and decent solution behavior (Supplementary information, Fig. S1). This variant was named Ca<sub>v</sub>3.2EM, as it was used for cryogenic electron microscopy (cryo-EM) imaging.

The biophysical properties of Ca<sub>v</sub>3.2EM were verified through whole-cell patch-clamp recordings. Consistent with its improved protein expression, Ca<sub>v</sub>3.2EM exhibited an increased conductance compared with the wild-type (WT) channel. Additionally, both the activation and steady-state inactivation curves of Ca<sub>v</sub>3.2EM demonstrated a slight leftward shift in comparison to WT (Fig. 1a; Supplementary information, Fig. S2 and Table S1).

Following the functional validation of Ca<sub>v</sub>3.2EM, we performed standard cryo-EM single particle analysis and obtained a three-dimensional (3D) EM reconstruction at an overall resolution of 3.0 Å. This structure is henceforth referred to as Ca<sub>v</sub>3.2Apo. Two glycan chains were observed, attaching to Asn345 and Asn1466 in the extracellular loops in repeats I and III (ECL<sub>I</sub> and ECL<sub>III</sub>) via N-link (Fig. 1b; Supplementary information, Figs. S3, S4 and Table S2). Previous studies have also suggested the importance of these N-glycosylation sites in regulating the functional expression of Ca<sub>v</sub>3.2.<sup>50–52</sup>

The overall structure of Ca<sub>v</sub>3.2Apo displays an inactivated state nearly identical to that observed for Ca<sub>v</sub>3.1 and Ca<sub>v</sub>3.3,<sup>44,47</sup> with root-mean-square deviations (RMSDs) of 0.58 Å over 847 Ca atoms and 1.16 Å over 948 Ca atoms, respectively (Fig. 1c). All four voltage-sensing domains (VSDs) adopt the depolarized or “up” conformation, and the intracellular gate is tightly twisted. The closed intracellular gate comprises three layers of hydrophobic residues. The first assembly site beneath the central cavity includes conserved residues Leu415, Leu1010, Phe1550, and Val1855, a common feature observed in the structures of all three members of Ca<sub>v</sub>3 channels (Fig. 1d). A spherical density, likely corresponding to a Ca<sup>2+</sup> ion, is surrounded by four residues, Glu378, Glu974, Asp1504, and Asp1808 (the EEDD motif) in the selectivity filter (SF) (Fig. 1e).

### Structural determination of Ca<sub>v</sub>3.2 with different antagonists

Next, we set out to determine the structures of Ca<sub>v</sub>3.2 in complex with representative T-type channel-selective antagonists. To validate the action of these compounds on both WT Ca<sub>v</sub>3.2 channel and Ca<sub>v</sub>3.2EM variant, we conducted whole-cell patch-clamp recordings in HEK293T cells (Supplementary information, Fig. S5 and Tables S3, S4). The characterizations indicated that Ca<sub>v</sub>3.2EM exhibited comparable potency across all tested compounds compared to the WT channel. Each antagonist was individually incubated with purified Ca<sub>v</sub>3.2 protein at a final concentration at least 10-fold higher than its IC<sub>50</sub> value before cryo-sample preparation. Following similar protocols for cryo-EM data acquisition and analysis, we successfully resolved the structures of Ca<sub>v</sub>3.2 in complex with four compounds, ACT-

709478, TTA-A2, TTA-P2, and ML218, with overall resolutions ranging from 2.8 Å to 3.2 Å. For simplicity, we will refer to these structures as Ca<sub>v</sub>3.2-ACT/TA/TP/ML, with “ACT” representing ACT-709478, “TA” for TTA-A2, “TP” for TTA-P2, and “ML” for ML218 (Supplementary information, Fig. S6 and Table S2).

All four complex structures resemble the apo form, with the compounds each accommodated within the pore domain (PD) (Supplementary information, Fig. S6q). The four compounds can be further categorized into two groups: ACT-709478 and TTA-A2 insert through the IV-I fenestration, while TTA-P2 and ML218 dock on the II-III fenestration. Apart from the fenestration binding site, the other end of these elongated compounds is nestled within the central cavity. The fenestration-accommodating binding poses immediately suggest the molecular basis for their state-dependent pore-blocking mechanism. In the following text, we will illustrate their binding details, which will facilitate future drug design and optimization.

### Coordination of ACT-709478 and TTA-A2

Both ACT-709478 and TTA-A2 were well resolved. The distinct structural features within the densities, like the trifluoromethyl group in ACT-709478 and the methyl group in TTA-A2, enabled reliable model building of these small-molecule compounds (Supplementary information, Fig. S6).


The head groups, characterized by the cyclopropylphenyl group in TTA-A2 or the trifluoromethyl cyclopropylphenyl moiety in ACT-709478, reside in the center of the cavity, which we named site C in Na<sub>v</sub> channels<sup>53,54</sup> (Fig. 2a, b). These groups are coordinated similarly by several hydrophobic residues from the S6 tetrahelical bundles, including Phe408 and Asn412 on S6<sub>I</sub>, Phe1007 and Leu1010 on S6<sub>II</sub>, Val1546, Leu1547, and Phe1550 on S6<sub>III</sub>, and Gln1848, Leu1851, and Val1852 on S6<sub>IV</sub> (Fig. 2c, d).

Both tail groups, despite their distinct chemical structures, wedge into the IV-I fenestration, indicating the fenestration’s versatile adaptability to diverse molecules. Per our recently proposed nomenclature system for the druggable sites on Na<sub>v</sub> channels,<sup>53</sup> this site will be described as site F4. The tail groups in the IV-I fenestration are surrounded by hydrophobic residues, Leu377, Ile403, Ser407, and Phe408 from repeat I, as well as Phe1756, Phe1802, Ser1805, and Thr1806 from repeat IV. In the case of ACT-709478, the nitrogen within the cyanopyridine ring is further stabilized through a hydrogen bond (H-bond) with the hydroxyl group from Ser1805. Furthermore, both internal amide linkages are H-bonded with Asn412 and Gln1848, contributing to the stability of these unique binding poses (Fig. 2c, d).

### An α-to-π transition of S6<sub>II</sub> in the presence of TTA-A2

ACT-709478 and TTA-A2 share a similar pharmacophore featuring a cyclopropylphenyl head, an aromatic tail, and an amide linkage. However, there are local structural variations in the presence of these two compounds. While the conformation of Ca<sub>v</sub>3.2-ACT is nearly identical to that of the apo channel, structural rearrangements occur in the presence of TTA-A2, as exemplified by an α-to-π transition in the middle of the S6<sub>II</sub> segment (Fig. 3a).

A close structural comparison of Ca<sub>v</sub>3.2-ACT/TA reveals that the conformational deviation is caused by the minor difference in the head group. The only divergence of the head group of the two molecules pertains to the presence of an additional trifluoromethyl group in ACT-709478. This protrusion would clash with Phe1007 in a π-helical configuration but align well with the α-helix. Yet, Phe1007 provides a favorable environment for accommodating the smaller cyclopropylphenyl group in TTA-A2, explaining the π form of S6<sub>II</sub> in Ca<sub>v</sub>3.2-TA (Fig. 3a). As a result of the minor rotation of Phe1007, the I-II fenestration, present in the apo channel and Ca<sub>v</sub>3.2-ACT, diminishes in Ca<sub>v</sub>3.2-TA, and the gating residue on S6<sub>II</sub> shifts from Leu1010 to Val1011 in Ca<sub>v</sub>3.2-TA, with the intracellular gate remaining closed (Figs. 1d, 3b; Supplementary information, Fig. S7).




**Fig. 1 Cryo-EM structural analysis of human  $\text{Ca}_v3.2$ .** **a** Electrophysiological characterizations of full-length human  $\text{Ca}_v3.2\text{WT}$  (black) and truncated  $\text{Ca}_v3.2\text{EM}$  (red) in HEK293T cells. Voltage-dependent activation and steady-state inactivation curves are presented in the upper and lower panels, respectively.  $n$  values indicate the number of independent cells; data are presented as mean  $\pm$  SEM. Please refer to Materials and Methods and Supplementary information for details. **b** Cryo-EM reconstruction of human  $\text{Ca}_v3.2\text{EM}$ . The EM map is color-coded for the four repeats (upper left), and the sugar moieties and lipids are colored bright and pale orange, respectively. The same color scheme is applied throughout the manuscript. The overall structure of human  $\text{Ca}_v3.2$  is shown in a side view (upper right) and top view (bottom). **c** Structural comparison of the three T-type  $\text{Ca}_v$  channels:  $\text{Ca}_v3.1$  (PDB: 6KZO, light green),  $\text{Ca}_v3.2$  (domain colored), and  $\text{Ca}_v3.3$  (PDB: 7WLI, pink). **d** The ion-conducting path of  $\text{Ca}_v3.2$  is calculated in HOLE<sup>70</sup> and illustrated with purple dots (left). The calculated pore radii along the permeation path are depicted as a purple line (middle). Two constriction sites, the SF enclosed by the EEDD motif and the intracellular gate, are shown on the right, in extracellular views. **e**  $\text{Ca}^{2+}$  coordination in the SF. Densities for the SF, prepared in ChimeraX, are contoured at the level of  $4\sigma$ , and the potential  $\text{Ca}^{2+}$  ion is shown as a green sphere.

#### TTA-P2 and ML218 bind through the II-III fenestration

TTA-P2 and ML218 also share a similar chemical structure, characterized by a 3,5-dichlorobenzamide head and an aliphatic tail (Fig. 4a). They also display a similar binding paradigm, with the head adhering to the II-III fenestration (Site F2), and the tail projecting into the cavity (site C) (Fig. 4b). Despite an  $\sim 30^\circ$  deviation of the binding poses for the two head groups, the accommodation site within the fenestration is similar. The environment is primarily hydrophobic, enclosed by residues from

$\text{S5}_{\text{II}}$ ,  $\text{P1}_{\text{II}}$ ,  $\text{S6}_{\text{II}}$ , and  $\text{S6}_{\text{III}}$  segments, including Leu922 on  $\text{S5}_{\text{II}}$ , Leu971 on  $\text{P1}_{\text{II}}$ , Asn1003 and Phe1007 on  $\text{S6}_{\text{II}}$ , Lys1503 in the P-loop, and Leu1539, Ser1543, Leu1547, and Phe1550 on  $\text{S6}_{\text{III}}$  (Fig. 4c, d).

The aliphatic tail of both TTA-P2 and ML218 reclines across the central cavity, directly obstructing ion permeation. The cavity site is formed by Leu415 on  $\text{S1}_{\text{I}}$ , Phe1007 on  $\text{S6}_{\text{II}}$ , and Ser1543, Leu1547, and Phe1550 on  $\text{S6}_{\text{III}}$  (Fig. 4d, e). Similar to the conformation observed in the presence of TTA-A2,  $\text{S6}_{\text{II}}$  adopts a  $\pi$ -helix conformation upon binding to TTA-P2 or ML218. On one



**Fig. 2 Molecular basis for  $\text{Ca}_v3.2$  inhibition by ACT-709478 or TTA-A2.** **a** Chemical structures of ACT-709478 and TTA-A2. The two compounds share a common core structure, featuring a cyclopropylphenyl head (highlighted in red), an aromatic tail (highlighted in green), and an amide linker. **b** Structural basis for pore block by ACT-709478 or TTA-A2. Both molecules traverse the central cavity, with one end inserting into the IV-I fenestration. The two structures, named  $\text{Ca}_v3.2$ -ACT and  $\text{Ca}_v3.2$ -TA, are superimposed relative to the PD. ACT-709478 and TTA-A2 are shown as brown and black sticks, respectively, and only the PD of  $\text{Ca}_v3.2$ -ACT is shown. **c** Detailed coordination of ACT-709478 and TTA-A2. The aromatic tail groups of ACT-709478 and TTA-A2, which vary in details, can both be accommodated in the IV-I fenestration. Potential H-bonds are highlighted with red dashed lines. **d** Schematic representation of residues constituting the binding site for ACT-709478 (upper) and TTA-A2 (lower). Residues within a 4 Å cutoff distance to the ligand are shown, with the binding pocket and potential H-bonds indicated by gray dashed contour and red dashed lines, respectively.

end, the 3,5-dichlorobenzamide head group would encounter spatial repulsion with Leu1006 in an  $\alpha$ -helix conformation; on the other end, the aliphatic tail could be further stabilized by Phe1007 through a  $\pi$ -H interaction, thus favoring the  $\pi$ -helix form (Fig. 4f).

#### Stabilization of antagonist binding by an endogenous lipid


Examination of the 3D EM maps for all the structures, including that of the apo channel, identifies a well-resolved density in the cavity, which can be best fitted with a phosphatidylethanolamine (PE) molecule (Fig. 5a, b; Supplementary information, Fig. S8). The two hydrophobic tails penetrate the III-IV fenestration, and the polar head inserts into the central cavity, directly contributing to drug coordination. Similar paradigm has been observed in drug-bound structures of  $\text{Ca}_v1.1$ ,  $\text{Ca}_v3.1$ , and  $\text{Ca}_v3.3$ .<sup>22,44,47</sup>

To investigate the role of the lipid in drug binding, we performed molecular docking simulations with or without the lipid. The docking poses in the presence of the lipid align well with

the experimental structures, with RMSD values of the predicted binding poses  $< 3.0$  Å compared to the corresponding experimental structures. In contrast, in the absence of the lipid, the antagonists display more diverse docking poses, resulting in a broader range of RMSD and  $\Delta G_{\text{binding}}$  values (Fig. 5a, c). Among these, flipped poses are even more favored for ACT-709478 and TTA-A2 in the absence of the lipid (Fig. 5a). Our computational analyses support the role of the lipid in stabilizing the accommodation of the antagonists in the cavity, yet the physiological relevance and the identity and specificity of the endogenous lipids that may facilitate drug binding awaits further characterizations.

#### Structural basis for ligand selectivity on T-type $\text{Ca}_v$ channels

The four structures presented here, along with our previously reported  $\text{Ca}_v3.1$ -Z944 complex structure,<sup>44</sup> offer important insights into T type-specific inhibition by these selective



**Fig. 3** Local structural shifts in the presence of TTA-A2. **a** An  $\alpha$ -to- $\pi$  transition observed in the S6<sub>II</sub> segment upon TTA-A2 binding. Left: Red arrows indicate the structural differences between Ca<sub>v</sub>3.2-ACT (gray) and Ca<sub>v</sub>3.2-TA (domain colored). An enlarged view that highlights the change of S6<sub>II</sub> is shown in the inset. Right: Rotation of the bottom half of the S6<sub>II</sub> helix in the presence of TTA-A2, but not ACT-709478. **b** Closure of the I-II fenestration in Ca<sub>v</sub>3.2-TA. Corresponding surface views of the four sides of the PD are presented for Ca<sub>v</sub>3.2-ACT (upper) and Ca<sub>v</sub>3.2-TA (lower).

antagonists. Sequence alignment reveals that several residues involved in ligand binding, including Leu377, Gln973, Phe1007, Leu1010, Val1011, Lys1503, Leu1539, Leu1540, Ser1543, Val1546, Leu1547, Phe1556, Ser1805, Gln1848, Leu1851, Val1852, and Val1855, most of which are positioned on the P-loops and the S6 tetrahelical bundle, vary from those in the HVA Ca<sub>v</sub> channels (Fig. 6a).

To identify the residues that underlie the subtype-specific sensitivity to these inhibitors, we started with *in silico* molecular docking and binding free energy calculation for Ca<sub>v</sub>3.2 mutants each with a single locus substituted with the corresponding residue from the HVA channels (Supplementary information, Fig. S9a). The computational analysis suggests that many mutations would have distinct impact on different inhibitors. For example, L377M, Q1848A/S, and L1851V/I/M resulted in decreased binding energy for ACT-709478 and TTA-A2, but not TTA-P2 or ML218. On the other hand, F1007L reduces the affinity to TTA-A2 and ML218, but has little effect on ACT-709478 and TTA-P2 (Supplementary information, Fig. S9).


Based on these clues, we generated a number of corresponding Ca<sub>v</sub>3.2 mutants and characterized their responses to the drugs using whole-cell patch-clamp recordings in HEK293T cells. Several mutations indeed attenuate the potency of the drugs, as exemplified by L377M, F1007L, Q1848A, L1851M and L1851I for TTA-A2, and F1007L for ML218. Consistent with the computational results, F1007L shows little effect on the potency of TTA-P2, which shares a similar binding pose to ML218 (Fig. 6b–d; Supplementary information, Figs. S9–S11 and Tables S3, S4).

The difference in F1007L's responses to ML218 and TTA-P2 may be attributed to the additional fluorine atom in the piperidine

of TTA-P2, which interferes with the  $\pi$ -H interaction between Phe1007 and the piperidine ring, leading to an  $\sim 30^\circ$  deviation of the binding poses for the 3,5-dichlorobenzamide heads. Therefore, the potency of TTA-P2 on Ca<sub>v</sub>3.2, regardless of the F1007L mutation, is lower than that of ML218 (Fig. 6c–e; Supplementary information, Fig. S9, Table S4). As there is no fluorine atom in the piperidine group of Z944, an analog of ML218 and TTA-P2, we also performed similar analysis on the complex structure of Z944-bound Ca<sub>v</sub>3.1. Its overall binding pose in Ca<sub>v</sub>3.1 is closer to that of ML218 in Ca<sub>v</sub>3.2 than TTA-P2. Replacing the allelic Phe956 with Leu in Ca<sub>v</sub>3.1 significantly reduces the potency of Z944 on Ca<sub>v</sub>3.1 in a similar manner to that of ML218 on Ca<sub>v</sub>3.2,<sup>44</sup> thereby confirming the distinct sensitivity of Phe1007 in Ca<sub>v</sub>3.2, or Phe956 in Ca<sub>v</sub>3.1, in ligand recognition (Supplementary information, Figs. S9–S11 and Table S4).

It is noted that K1503F or K1503G, which only slightly affects the binding energy, does not show a significant impact on the potency of ML218 on Ca<sub>v</sub>3.2 (Fig. 6d). A re-examination of the Z944 response by the corresponding Ca<sub>v</sub>3.1 mutants, K1462F or K1462G, reveals some technical issues in the previous electrophysiological characterizations, which are summarized in the legend of Supplementary information, Table S4. Using a corrected protocol, we show that K1462F or K1462G does not reduce Ca<sub>v</sub>3.1's sensitivity to Z944 either (Supplementary information, Table S4).<sup>44</sup>

Taken together, our structural, computational, and functional analyses reveal the complexity underlying the determinants for the subtype specificity by selective inhibitors, and suggest that targeting these critical residues could be a viable strategy for designing selective T-type Ca<sub>v</sub> channel blockers.



**Fig. 4 Specific inhibition of  $\text{Ca}_v3.2$  by ML218 or TTA-P2.** **a** Chemical structures of ML218 and TTA-P2. **b** The two molecules exhibit similar binding poses. Structures of  $\text{Ca}_v3.2\text{-ML}$  (with ML218) and  $\text{Ca}_v3.2\text{-TP}$  (with TTA-P2) are superimposed relative to the PD. Only the PD structure of  $\text{Ca}_v3.2\text{-ML}$  is shown as semi-transparent cartoon. **c** The binding poses of ML218 and TTA-P2 deviate with an  $\sim 30^\circ$  rotation of the 3,5-dichlorobenzamide head within the II-III fenestration. Detailed coordination of ML218 and TTA-P2 in the II-III fenestration are presented in the middle and right panels, respectively. **d** Schematic representation of residues constituting the binding site for ML218 or TTA-P2 within a 4-Å cutoff distance. The binding pocket and potential H-bonds are indicated by a gray dashed contour and red dashed lines, respectively. **e** Coordination of the aliphatic tail of the two compounds in the central cavity of  $\text{Ca}_v3.2$ . **f** Both structures adopt a  $\pi$  configuration in the middle of the S6<sub>II</sub> segment.


## DISCUSSION

Given its pivotal role in epilepsy and pain,  $\text{Ca}_v3.2$  has emerged as a promising target for the development of anti-epileptics and analgesics.<sup>39,55</sup> Dozens of pathological mutations, including those associated with autism, amyotrophic lateral sclerosis, hyperaldosteronism familial 4, and epilepsy, are directly linked to  $\text{Ca}_v3.2$  (Supplementary information, Table S5).<sup>38,56–60</sup> The high-resolution structures of  $\text{Ca}_v3.2$  enable precise mapping of nineteen mutations located in the resolved regions. These mutations exhibit widespread distribution across various VSDs, ECLs, and the pore (Supplementary information, Fig. S12), establishing a structural foundation for understanding disease mechanisms.

The structures reported here and previously<sup>44,47</sup> together reveal a common paradigm for T-type channel-selective pore blockers (Fig. 7a). These elongated molecules directly obstruct ion flow by occupying site C; meanwhile, the other end targets either site F2 (TTA-P2, ML218, Z944, pimozide, mibefradil, and otilonium bromide) or site F4 (ACT-709478 and TTA-A2) to stabilize the inactivated state. It is noted that the DHP compounds selectively

target the III-IV fenestration (site F3) of  $\text{Ca}_v1$  channels, which are also known as the DHP receptors,<sup>21</sup> while sites F2, F4, and C appear to be the promising regions in the T-type channels for developing selective blockers. Further chemical modifications of critical residues hold the promise to alter drug sensitivity and selectivity, providing opportunities for precise modulation of  $\text{Ca}_v$  subtypes.

Except  $\text{Ca}_v3.2\text{-ACT}$ , which remains unchanged from the apo channel, a conserved  $\alpha$ -to- $\pi$  transition in the middle of the S6<sub>II</sub> segment of all T-type channels is found in the presence of all other antagonists (Fig. 7b). Such secondary structural transition is also frequently observed in  $\text{Na}_v$  channels bound with pore blockers or even gating modifier toxins which bind to VSDs.<sup>61</sup> The  $\pi$ -form S6 is usually associated with sealed fenestration(s), shrunk cavity volume, and contracted intracellular gate, physical features that all antagonize channel conductance. This observation suggests that the  $\pi$ -form structures might represent potentially more favored templates for  $\text{Ca}_v$ - or  $\text{Na}_v$ -targeting drug design.



**Fig. 5 Stabilization of antagonist binding by endogenous lipids.** **a** A conserved endogenous lipid stabilizes antagonist association within the central cavity. The EM densities for the lipid and antagonist are contoured at the similar level of 4.5–5  $\sigma$ . The antagonists show more diverse docking poses in the absence of the endogenous lipid. Predicted binding poses in the absence of the lipid are represented as semi-transparent sticks, while the structure-determined binding pose is shown as solid sticks. **b** Identical binding pose of the lipid in all blocker-bound Ca<sub>v</sub>3.2 structures. Only the pore-forming helices of Ca<sub>v</sub>3.2-TA are shown in an extracellular view of the superimposed structures of the antagonist-bound pore cavity. **c** Less favored binding of antagonists to Ca<sub>v</sub>3.2 in the absence of the lipid. Predicted binding poses in the absence of the endogenous lipid exhibit larger variability, as indicated by the increased RMSD values. The average binding free energy ( $\Delta G_{\text{binding}}$ ) was calculated using Prime-MM/GBSA.

Last but not least, small molecule interactions within the scaffold of the spacious cavity have been manifested by the drug-drug interaction between the antiviral sofosbuvir/MNI-1 and the anti-arrhythmic amiodarone in the PD of Ca<sub>v</sub>1 channels.<sup>15,62</sup> Endogenous lipids also represent an important class of small molecules. It is therefore not surprising that one or even more phospholipid molecules might interfere with antagonist binding by modifying the contour and chemical composition of the binding pocket. The role of lipids and other endogenous molecules, such as hormones and metabolites, in drug binding should also be investigated when targeting voltage-gated ion channels for drug discovery.

## MATERIALS AND METHODS

### Transient expression of human Ca<sub>v</sub>3.2 in HEK293F cells


The codon-optimized cDNA of human *CACNA1H* for Ca<sub>v</sub>3.2 isoform 1 (2353 residues, Uniprot Q95180-1) was synthesized by BGI Geneland Scientific Co., Ltd. To generate Ca<sub>v</sub>3.2EM, residues 493–772 were deleted using a standard two-step PCR method. Both the full-length Ca<sub>v</sub>3.2 and the truncated Ca<sub>v</sub>3.2EM were subcloned into the pCAG vector with Twin-Strep-tag and Flag-tag in tandem at the amino terminus. All the plasmids for transient expression were confirmed through DNA sequencing. HEK293F suspension cells (Thermo Fisher Scientific, R79007) were cultured in FreeStyle 293 medium (Thermo Fisher Scientific) at 37 °C, supplied with 5% CO<sub>2</sub> under 60% humidity. Transfection of the cells with plasmids was carried out when the cell density reached 1.5–2.0 × 10<sup>6</sup> cells/mL. For each

1-L cell culture, a mixture of 1.5 mg expression plasmids for Ca<sub>v</sub>3.2 and 3 mg 40-kDa linear polyethylenimines (Polysciences) in 50 mL fresh medium was incubated for 15–30 min, and then added to the cell culture to achieve transient expression of the human Ca<sub>v</sub>3.2 complex.

### Preparation of Ca<sub>v</sub>3.2 alone and drug-bound complexes

For one batch of protein purification, 15 L of transfected HEK293F cells were harvested ~48 h after transfection by centrifugation at 3600 × *g* for 10 min and resuspended in the lysis buffer containing 25 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl<sub>2</sub> and protease inhibitor cocktail (Selleckchem). After sonication on ice, the suspension was supplemented with n-dodecyl- $\beta$ -D-maltopyranoside (Anatrace) to a final concentration of 1% (w/v), and cholesteryl hemisuccinate Tris salt (Anatrace) to 0.1% (w/v). After incubation at 4 °C for 2 h, the mixture was centrifuged at 16,000 × *g* for 45 min, and the supernatant was applied to anti-Flag M2 affinity gel (Sigma) for affinity purification. The resin was rinsed five times with the wash buffer (buffer W) that contains 25 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl<sub>2</sub>, 0.06% GDN, and protease inhibitor cocktail. The target proteins were eluted with buffer W supplemented with 0.2 mg/mL Flag peptide (synthesized by GenScript). The eluent was concentrated using a 100-kDa cut-off Amicon filter unit (Millipore) and further purified through size-exclusion chromatography (Superose 6 10/300 GL, GE Healthcare) that was pre-equilibrated in the buffer containing 25 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl<sub>2</sub> and 0.02% GDN. Among the tested constructs of Ca<sub>v</sub>3.2, Ca<sub>v</sub>3.2EM afforded decent protein yield that was suitable for cryo-EM analysis. The peak fractions were pooled and concentrated to a final concentration of ~12 mg/mL.





**Fig. 6 Structural basis for antagonist selectivity on T-type Ca<sub>v</sub> channels.** **a** Structure-guided sequence analysis to identify the determinants for antagonist selectivity. Sequence comparison of human Ca<sub>v</sub> channels for the antagonist-binding residues is shown. The dashes represent residues in other subtypes that are identical to the corresponding ones in Ca<sub>v</sub>3.2. **b** Functional validation of residues critical to TTA-A2 selectivity. Several residues in Ca<sub>v</sub>3.2 were mutated to corresponding ones in the HVA channels. The responses of these mutants to TTA-A2 were examined through whole-cell patch-clamp recordings. **c** A magnified view of the coordination of TTA-P2 and ML218 in the superimposed structures of Ca<sub>v</sub>3.2-TP and Ca<sub>v</sub>3.2-ML. **d** F1007L confers Ca<sub>v</sub>3.2 resistance to ML218, but not TTA-P2. Experimental details are provided in Materials and Methods and Supplementary information, Figs. S9–S11, and Tables S3 and S4. **e** Potential molecular basis for the distinct responses to TTA-P2 and ML218 by Ca<sub>v</sub>3.2-F1007L. The additional fluorine atom in the piperidine ring of TTA-P2 may interfere with the essential  $\pi$ -H interaction between Phe1007 and the piperidine ring, potentially resulting in lower potency on Ca<sub>v</sub>3.2, which is largely unaffected by the Leu substitution.

To prepare drug-bound complexes, different drug (ACT-709478, TTA-A2, TTA-P2, or ML218) was added to concentrated Ca<sub>v</sub>3.2 proteins at the final concentration of 1 mM, and the mixtures were incubated at 4 °C for 45 min before preparation of cryo-EM grids.


#### Cryo-EM sample preparation and data acquisition

The Quantifoil grids (R1.2/1.3 300 mesh, Quantifoil) or UltrAuFoil grids (R1.2/1.3 300 mesh, Quantifoil) underwent glow-discharge using easiGlow (PELCO) at 15 mA for 15 s at 0.37 mBar. Prior to sample application, the Vitrobot Mark IV chamber was pre-cooled to 10 °C with 100% humidity. Subsequently, 3  $\mu$ L of concentrated Ca<sub>v</sub>3.2-Apo/ACT/TA/TP/ML sample was applied to the freshly treated grid surface, followed by blotting with filter paper for 4 s. The grid was then swiftly plunged into liquid ethane and stored in liquid nitrogen.

For automated data collection, the grids were loaded onto a 300 kV Titan Krios G4 (Thermo Fisher) equipped with a Falcon IV detector (Thermo Fisher). Micrographs were captured using EPU (Thermo Fisher) in Falcon IV EC mode at a nominal magnification of 75,000 $\times$ , resulting in a calibrated pixel size of 1.036 Å. Each movie stack in EER format was exposed for 6 s, accumulating a total electron dose of  $\sim$ 40 e<sup>-</sup>/Å<sup>2</sup>. Subsequently, the movie stacks underwent alignment, summation, and dose-weighting using cryoSPARC live.<sup>63</sup>

#### Cryo-EM data processing

A total of 2,954/4,999/5,775/4,614/5,241 cryo-EM micrographs were collected for Ca<sub>v</sub>3.2-Apo/ACT/TA/TP/ML, respectively. During cryoSPARC live preprocessing, patched CTF estimation was implemented. For the Ca<sub>v</sub>3.2Apo dataset, 504 particles from 25 micrographs were manually



**Fig. 7** Structural mapping of drug-binding sites within the central cavity of T-type  $\text{Ca}_v$  channels. **a** Small-molecule T-type  $\text{Ca}_v$  blockers generally exhibit two binding poses within the cavity. Shown here are two perpendicular views of the superimposed PD of T-type  $\text{Ca}_v$  channels with inhibitors bound to the central cavity. TTA-A2 and ACT-709478 interact with the IV-I fenestration, while all others are associated with the II-III fenestration. **b** A common  $\alpha \rightarrow \pi$  transition of the  $\text{S6}_{\text{II}}$  segment when accommodating different antagonists. Among the various resolved structures of T-type  $\text{Ca}_v$  channels in complex with antagonists, ACT-709478 is the only one that binds to the  $\alpha$  form.

picked to generate 2D templates through 2D classification. Subsequently, 1,812,275 particles were picked using the selected 2D templates through the template picker, and 2D classification was performed with bin-4 particles. 2D Class averages with different views were chosen as new references for the template picker. Two batches of picked particles underwent independent 2D classifications, and the well-classified particles were selected and merged. The  $\text{Ca}_v3.1$  structure (EMD-0791) was low-pass filtered and, together with a decoy junk density, used for heterogeneous refinement with bin-4 particles. The best class was selected and re-extracted to bin-2 for multiple rounds of continuous heterogeneous refinement. Subsequently, 565,821 particles were re-extracted into bin1 and subjected to another three rounds of heterogeneous refinement, resulting in a 3.4 Å NU-refinement result. This map was applied as a new heterogeneous refinement reference, considering higher frequency information. Through additional rounds of heterogeneous refinement and a final clean-up round of 2D classification, 103,429 particles were selected, leading to a reconstruction at 3.0 Å. A similar processing workflow was applied to other ligand-bound  $\text{Ca}_v3.2$  datasets, utilizing the apo-structure as the initial model.

### Model building and refinement

The  $\text{Ca}_v3.2$  apo initial model was automatically generated with ModelAngelo<sup>64</sup> and subsequently subjected to manual examination and adjustments in COOT.<sup>65</sup> Refinement against the corresponding map was then executed using the Real-space Refinement option in PHENIX.<sup>66</sup> Additional structure optimization was conducted with ISOLDE,<sup>67</sup> followed by a conclusive round of Real-space Refinement in PHENIX. The apo structure served as the new initial model for ligand-bound structures, employing the same model-building process. Detailed validation results for the model refinement are presented in Supplementary information, Table S2.

### Whole-cell electrophysiology

HEK293T cells were cultured in Dulbecco's Modified Eagle Medium (BI) supplemented with 4.5 mg/mL glucose and 10% (v/v) fetal bovine serum (BI). For patch-clamp recordings, the cells were plated onto glass coverslips and transiently co-transfected with the  $\text{Ca}_v3.2$  variant plasmids and eGFP in the presence of lipofectamine 2000 (Invitrogen). Cells with green fluorescence were selected for patch-clamp recording 18–36 h after transfection. Experiments were performed at room temperature. No authentication was performed for the commercially available cell line. Mycoplasma contamination was not tested.

Whole-cell  $\text{Ca}_v3.2$   $\text{Ca}^{2+}$  currents were recorded in HEK293T cells using an EPC10-USB amplifier with Patchmaster software v2\*90.2 (HEKA Elektronik), filtered at 3 kHz (low-pass Bessel filter) and sampled at 50 kHz. The borosilicate pipettes (Sutter Instrument) used in all experiments had a

resistance of 2–4 M $\Omega$  and series resistance was compensated by 70%–80%. The electrodes were filled with the internal solution composed of 125 mM CsCl, 10 mM EGTA, 2 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 5 mM  $\text{Na}_2\text{ATP}$ , 10 mM HEPES, pH adjusted to 7.4 with CsOH. The bath solutions contained 5 mM  $\text{CaCl}_2$ , 166 mM TEA-Cl, 10 mM HEPES, pH adjusted to 7.4 with TEA-OH. For the long-term drug delivery tests, the internal and external solutions were altered. The borosilicate pipettes were filled with a solution consisting of 130 mM Cs-methanesulfonate, 10 mM TEA-Cl, 10 mM EGTA, 5 mM  $\text{MgCl}_2$ , 5 mM Na-ATP, 10 mM HEPES (pH 7.4 with CsOH) with a resistance of 2–4 M $\Omega$ , whereas the bath solutions contained 110 mM CsCl, 40 mM TEA-Cl, 5 mM  $\text{BaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 10 mM  $\text{D}$ -glucose, and 10 mM HEPES (pH 7.4 with TEA-OH). Mutants with small currents were recorded with 10 mM  $\text{BaCl}_2$  in the external solution instead of 5 mM. Data were analyzed using Fitmaster 2.90.5 (HEKA Elektronik), Origin (OriginLab), and GraphPad Prism (GraphPad Software).

The voltage dependence of ion current ( $I$ - $V$ ) was analyzed using a protocol consisting of steps from a holding potential of  $-100$  mV for 200 ms to voltages ranging from  $-90$  mV to  $+50$  mV for 150 ms in 5 mV increments. The linear component of leaky currents and capacitive transients were subtracted using the P/4 procedure. For activation property analysis, the equation  $G = I/(V - V_r)$  was utilized, where  $V_r$ , the reversal potential, represents the voltage at which the current is zero. For the activation curves, conductance ( $G$ ) was normalized and plotted against the voltage from  $-90$  mV to 0 mV or 20 mV. For voltage-dependent steady-state inactivation, cells were clamped at a holding potential of  $-100$  mV and applied to step pre-pulses from  $-110$  mV to  $-10$  mV for 1000 ms with an increment of 5 mV. Subsequently, the  $\text{Ca}^{2+}$  currents were recorded at the test pulse of  $-30$  mV for 100 ms. The peak currents under the test pulses were normalized and plotted against the prepulse voltage. Activation and inactivation curves were fitted with a Boltzmann function to determine  $V_{1/2}$  and slope values. The time course of inactivation data from the peak current at  $-30$  mV was fitted with a single exponential equation:  $y = A_1 \exp(-x/\tau_{\text{inac}}) + y_0$ , where  $A_1$  was the relative fraction of current inactivation,  $\tau_{\text{inac}}$  was the time constant,  $x$  was the time, and  $y_0$  was the amplitude of the steady-state component.

To investigate the inhibition of  $\text{Ca}_v3.2$  variants by different drugs, cells were held at  $-100$  mV and stepped to  $-30$  mV for 150 ms. Drugs were dissolved in dimethyl sulfoxide (final concentration  $< 0.1\%$ , Sigma) to make a stock solution. Solutions with the indicated concentrations were freshly prepared and perfused to the recording cell for up to several minutes to achieve the maximal blockade using a multichannel perfusion system (VM8, ALA). Prior to drug perfusion, cells were recorded for 5 min to establish a stable peak current. The concentration-response curve was fitted using the equation  $Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{(\log \text{IC}_{50} - X) \times \text{Hill Slope}})$ , where  $\text{IC}_{50}$  represented the concentration of the drugs that blocked 50% of the current and  $X$  denoted the log of drug concentration, and Hill Slope indicated the slope factor.

Data are presented as mean  $\pm$  standard error of the mean (SEM), with  $n$  representing the number of experimental cells from which recordings were obtained. Statistical significance was assessed using an unpaired  $t$ -test with Welch's correction, one-way ANOVA analysis, and extra sum-of-squares  $F$  test.

### Molecular docking and binding free energy calculation

The molecular docking analysis employed the Schrödinger Suite 2018-1 (Schrödinger, Inc.). Initial 3D configurations of small molecules were generated and optimized using the LigPrep program<sup>68</sup> with the OPLS3 force field.<sup>69</sup> The protein structure was prepared using default settings within Protein Preparation Wizard, utilizing the coordinates from the Ca<sub>v</sub>3.2-drug complexes. Subsequently, molecular docking simulations were executed with the extra-precision docking method (Glide XP) in the Glide program. The top-scored binding pose aligns well with the binding pose resolved in the cryo-EM structure and was selected for further analysis. Subtype-specific residues within the drug-binding site were mutated based on sequence alignment to those in other subtypes. The Prime-molecular mechanics/generalized Born surface area (MM/GBSA) method was employed to calculate the relative binding free energy changes ( $\Delta\Delta G$ ) for each mutant compared to the WT, while keeping the ligand and other residues fixed.

### DATA AVAILABILITY

The data that support this study are available from the corresponding authors upon reasonable request. The cryo-EM maps have been deposited in the Electron Microscopy Data Bank (EMDB) under accession codes EMD-43991 (Ca<sub>v</sub>3.2Apo), EMD-43995 (Ca<sub>v</sub>3.2-ACT), EMD-43992 (Ca<sub>v</sub>3.2-TA), EMD-43993 (Ca<sub>v</sub>3.2-TP), and EMD-43994 (Ca<sub>v</sub>3.2-ML). The coordinates have been deposited in the Protein Data Bank (PDB) under accession codes 9AYG (Ca<sub>v</sub>3.2Apo), 9AYL (Ca<sub>v</sub>3.2-ACT), 9AYH (Ca<sub>v</sub>3.2-TA), 9AYJ (Ca<sub>v</sub>3.2-TP), and 9AYK (Ca<sub>v</sub>3.2-ML).

### REFERENCES

- Catterall, W. A. Voltage-gated calcium channels. *Cold Spring Harb. Perspect. Biol.* **3**, a003947 (2011).
- Dolphin, A. C. A short history of voltage-gated calcium channels. *Br. J. Pharmacol.* **147**(1), S56–S62 (2006).
- McDonald, T. F., Pelzer, S., Trautwein, W. & Pelzer, D. J. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. *Physiol. Rev.* **74**, 365–507 (1994).
- Clapham, D. E. Calcium signaling. *Cell* **131**, 1047–1058 (2007).
- Takahashi, M., Seagar, M. J., Jones, J. F., Reber, B. F. & Catterall, W. A. Subunit structure of dihydropyridine-sensitive calcium channels from skeletal muscle. *Proc. Natl. Acad. Sci. USA* **84**, 5478–5482 (1987).
- Van Goor, F., Zivadinovic, D., Martinez-Fuentes, A. J. & Stojilkovic, S. S. Dependence of pituitary hormone secretion on the pattern of spontaneous voltage-gated calcium influx. Cell type-specific action potential secretion coupling. *J. Biol. Chem.* **276**, 33840–33846 (2001).
- Olivera, B. M., Miljanich, G. P., Ramachandran, J. & Adams, M. E. Calcium channel diversity and neurotransmitter release: the omega-conotoxins and omega-agatoxins. *Annu. Rev. Biochem.* **63**, 823–867 (1994).
- Flavell, S. W. & Greengard, M. E. Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system. *Annu. Rev. Neurosci.* **31**, 563–590 (2008).
- Li, B., Tadross, M. R. & Tsien, R. W. Sequential ionic and conformational signaling by calcium channels drives neuronal gene expression. *Science* **351**, 863–867 (2016).
- Ben-Johny, M. & Yue, D. T. Calmodulin regulation (calmodulation) of voltage-gated calcium channels. *J. Gen. Physiol.* **143**, 679–692 (2014).
- Halling, D. B., Aracena-Parks, P. & Hamilton, S. L. Regulation of voltage-gated Ca<sup>2+</sup> channels by calmodulin. *Sci. STKE* **2005**, re15 (2005).
- Van Petegem, F., Chatelain, F. C. & Minor, D. L. Jr Insights into voltage-gated calcium channel regulation from the structure of the CaV1.2 IQ domain-Ca<sup>2+</sup>/calmodulin complex. *Nat. Struct. Mol. Biol.* **12**, 1108–1115 (2005).
- Suh, B. C., Leal, K. & Hille, B. Modulation of high-voltage activated Ca(2+) channels by membrane phosphatidylinositol 4,5-bisphosphate. *Neuron* **67**, 224–238 (2010).
- Yao, X. et al. Structures of the R-type human Ca(v)2.3 channel reveal conformational crosstalk of the intracellular segments. *Nat. Commun.* **13**, 7358 (2022).
- Gao, S. et al. Structural basis for human Ca(v)1.2 inhibition by multiple drugs and the neurotoxin calciseptine. *Cell* **186**, 5363–5374.e16 (2023).
- Dolphin, A. C. G protein modulation of voltage-gated calcium channels. *Pharmacol. Rev.* **55**, 607–627 (2003).
- Dolphin, A. C. Mechanisms of modulation of voltage-dependent calcium channels by G proteins. *J. Physiol.* **506**(1), 3–11 (1998).
- Wolfe, J. T., Wang, H., Howard, J., Garrison, J. C. & Barrett, P. Q. T-type calcium channel regulation by specific G-protein betagamma subunits. *Nature* **424**, 209–213 (2003).
- Catterall, W. A. et al. Voltage-gated ion channels and gating modifier toxins. *Toxicol.* **49**, 124–141 (2007).
- Catterall, W. A., Lenaeus, M. J. & Gamal El-Din, T. M. Structure and pharmacology of voltage-gated sodium and calcium channels. *Annu. Rev. Pharmacol. Toxicol.* **60**, 133–154 (2020).
- Zhao, Y. et al. Molecular basis for ligand modulation of a mammalian voltage-gated Ca(2+) channel. *Cell* **177**, 1495–1506.e12 (2019).
- Gao, S. & Yan, N. Structural basis of the modulation of the voltage-gated calcium ion channel Ca(v) 1.1 by dihydropyridine compounds\*. *Angew Chem. Int. Ed. Engl.* **60**, 3131–3137 (2021).
- Gao, S., Yao, X. & Yan, N. Structure of human Ca(v)2.2 channel blocked by the painkiller ziconotide. *Nature* **596**, 143–147 (2021).
- Neumaier, F., Dibue-Adjei, M., Hescheler, J. & Schneider, T. Voltage-gated calcium channels: Determinants of channel function and modulation by inorganic cations. *Prog. Neurobiol.* **129**, 1–36 (2015).
- Nowycky, M. C., Fox, A. P. & Tsien, R. W. Three types of neuronal calcium channel with different calcium agonist sensitivity. *Nature* **316**, 440–443 (1985).
- Ertel, E. A. et al. Nomenclature of voltage-gated calcium channels. *Neuron* **25**, 533–535 (2000).
- Catterall, W. A., Perez-Reyes, E., Snutch, T. P. & Striessnig, J. International union of pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. *Pharmacol. Rev.* **57**, 411–425 (2005).
- Doering, C. J. & Zamponi, G. W. Molecular pharmacology of high voltage-activated calcium channels. *J. Bioenerg. Biomembr.* **35**, 491–505 (2003).
- Perez-Reyes, E. Molecular characterization of T-type calcium channels. *Cell Calcium* **40**, 89–96 (2006).
- Arikath, J. & Campbell, K. P. Auxiliary subunits: essential components of the voltage-gated calcium channel complex. *Curr. Opin. Neurobiol.* **13**, 298–307 (2003).
- Randall, A. D. & Tsien, R. W. Contrasting biophysical and pharmacological properties of T-type and R-type calcium channels. *Neuropharmacology* **36**, 879–893 (1997).
- Perez-Reyes, E. Molecular physiology of low-voltage-activated t-type calcium channels. *Physiol. Rev.* **83**, 117–161 (2003).
- Talley, E. M. et al. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. *J. Neurosci.* **19**, 1895–1911 (1999).
- Francois, A. et al. The low-threshold calcium channel Cav3.2 determines low-threshold mechanoreceptor function. *Cell Rep.* **10**, 370–382 (2015).
- Bourinet, E. et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. *EMBO J.* **24**, 315–324 (2005).
- Cai, S., Gomez, K., Moutal, A. & Khanna, R. Targeting T-type/Cav3.2 channels for chronic pain. *Transl. Res.* **234**, 20–30 (2021).
- Choi, S. et al. Attenuated pain responses in mice lacking Ca(V)3.2 T-type channels. *Genes Brain Behav.* **6**, 425–431 (2007).
- Heron, S. E. et al. Genetic variation of CACNA1H in idiopathic generalized epilepsy. *Ann. Neurol.* **55**, 595–596 (2004).
- Khosravani, H. et al. Gating effects of mutations in the Cav3.2 T-type calcium channel associated with childhood absence epilepsy. *J. Biol. Chem.* **279**, 9681–9684 (2004).
- Snutch, T. P. & Zamponi, G. W. Recent advances in the development of T-type calcium channel blockers for pain intervention. *Br. J. Pharmacol.* **175**, 2375–2383 (2018).
- Matar, N. et al. Zonisamide block of cloned human T-type voltage-gated calcium channels. *Epilepsy Res.* **83**, 224–234 (2009).
- Perez-Reyes, E., Van Deusen, A. L. & Vitko, I. Molecular pharmacology of human Cav3.2 T-type Ca<sup>2+</sup> channels: block by antihypertensives, antiarrhythmics, and their analogs. *J. Pharmacol. Exp. Ther.* **328**, 621–627 (2009).
- Francois, A. et al. State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects. *Pain* **154**, 283–293 (2013).
- Zhao, Y. et al. Cryo-EM structures of apo and antagonist-bound human Ca(v)3.1. *Nature* **576**, 492–497 (2019).
- Xiang, Z. et al. The discovery and characterization of ML218: A novel, centrally active T-type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease. *ACS Chem. Neurosci.* **2**, 730–742 (2011).
- Nam, G. T-type calcium channel blockers: a patent review (2012–2018). *Expert Opin. Ther. Pat.* **28**, 883–901 (2018).

47. He, L. et al. Structure, gating, and pharmacology of human Ca(V)3.3 channel. *Nat. Commun.* **13**, 2084 (2022).
48. Montell, A. et al. Inhibition of Cav3.2 T-type calcium channels by its intracellular I-II loop. *J. Biol. Chem.* **290**, 16168–16176 (2015).
49. Shcheglovitov, A. et al. Alternative splicing within the I-II loop controls surface expression of T-type Ca(v)3.1 calcium channels. *FEBS Lett.* **582**, 3765–3770 (2008).
50. Weiss, N., Black, S. A., Bladen, C., Chen, L. & Zamponi, G. W. Surface expression and function of Cav3.2 T-type calcium channels are controlled by asparagine-linked glycosylation. *Pflugers Arch.* **465**, 1159–1170 (2013).
51. Fichelova, V. et al. Functional identification of potential non-canonical N-glycosylation sites within Ca(v)3.2 T-type calcium channels. *Mol. Brain* **13**, 149 (2020).
52. Orestes, P. et al. Reversal of neuropathic pain in diabetes by targeting glycosylation of Ca(V)3.2 T-type calcium channels. *Diabetes* **62**, 3828–3838 (2013).
53. Wu, Q. et al. Structural mapping of Na(v)1.7 antagonists. *Nat. Commun.* **14**, 3224 (2023).
54. Li, Z., Wu, Q. & Yan, N. A structural atlas of druggable sites on Na(v) channels. *Channels* **18**, 2287832 (2024).
55. Becker, A. J. et al. Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy. *J. Neurosci.* **28**, 13341–13353 (2008).
56. Vitko, I. et al. The I-II loop controls plasma membrane expression and gating of Ca(v)3.2 T-type Ca<sup>2+</sup> channels: a paradigm for childhood absence epilepsy mutations. *J. Neurosci.* **27**, 322–330 (2007).
57. Heron, S. E. et al. Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. *Ann. Neurol.* **62**, 560–568 (2007).
58. Splawski, I. et al. CACNA1H mutations in autism spectrum disorders. *J. Biol. Chem.* **281**, 22085–22091 (2006).
59. Rzhapetsky, Y., Lazniewska, J., Blesneac, I., Pamphlett, R. & Weiss, N. CACNA1H missense mutations associated with amyotrophic lateral sclerosis alter Cav3.2 T-type calcium channel activity and reticular thalamic neuron firing. *Channels* **10**, 466–477 (2016).
60. Stringer, R. N. et al. A rare CACNA1H variant associated with amyotrophic lateral sclerosis causes complete loss of Ca(v)3.2 T-type channel activity. *Mol. Brain* **13**, 33 (2020).
61. Huang, G. et al. High-resolution structures of human Na(v)1.7 reveal gating modulation through  $\alpha$ -n helical transition of S6(IV). *Cell Rep.* **39**, 110735 (2022).
62. Yao, X. et al. Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Ca(v) channels. *Cell* **185**, 4801–4810.e13 (2022).
63. Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat. Methods* **14**, 290–296 (2017).
64. Jamali, K. et al. Automated model building and protein identification in cryo-EM maps. *Nature* <https://doi.org/10.1038/s41586-024-07215-4> (2024).
65. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501 (2010).
66. Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. *Acta Crystallogr. D Struct. Biol.* **75**, 861–877 (2019).
67. Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. *Acta Crystallogr. D Struct. Biol.* **74**, 519–530 (2018).
68. Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J. Comput. Aided Mol. Des.* **27**, 221–234 (2013).
69. Harder, E. et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. *J. Chem. Theory Comput.* **12**, 281–296 (2016).
70. Smart, O. S., Neduvellil, J. G., Wang, X., Wallace, B. A. & Sansom, M. S. HOLE: a program for the analysis of the pore dimensions of ion channel structural models. *J. Mol. Graph* **14**, 354–360 (1996).

## ACKNOWLEDGEMENTS

We thank the cryo-EM facility at Princeton Imaging and Analysis Center. This work is supported by the National Institutes of Health (23307-G0001-10013397-101), the National Natural Science Foundation of China (32330052), Beijing Frontier Research Center for Biological Structure, and Start-up funds from Tsinghua University. N.Y. was supported by the Shirley M. Tilghman endowed professorship from Princeton University in 2017–2022. X.F. has been supported by the HFSP long-term fellowship (LT000754/2020-L) from the International Human Frontier Science Program Organization (HFSP) from 2020 to 2023.

## AUTHOR CONTRIBUTIONS

N.Y., J.H. and X.F. conceived the project. J.H., X.F., X.J., J.C., C.L., Q.G., T.L., A.D., P.L. and N.Y. designed experiments; J.H. and X.F. performed all experiments related to cryo-EM studies, including protein expression and purification; J.H. performed all computational simulations, including molecular docking and binding free energy calculations; X.J., J.C., C.L., Q.G. and T.L. carried out experiments related to electrophysiology; J.H., X.F., X.J., J.C., C.L., Q.G., T.L., A.D., P.L. and N.Y. analyzed the data; J.H., X.F., X.J., and N.Y. wrote the manuscript with input from all authors. All authors approved the final manuscript.

## COMPETING INTERESTS

The authors declare no competing interests.

## ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41422-024-00959-8>.

**Correspondence** and requests for materials should be addressed to Xiao Fan or Nieng Yan.

**Reprints and permission information** is available at <http://www.nature.com/reprints>



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024